LAVA Therapeutics (LVTX) Stock Price, News & Analysis

Company Overview

LAVA Therapeutics is a clinical-stage biotechnology company focused on developing next-generation immunotherapies that leverage the body’s innate gamma-delta T cells to target cancer. The company’s proprietary “Gammabody” platform is designed to engage and activate these unique immune cells through small, bispecific mini-antibodies. By harnessing the natural tumor-seeking properties of gamma-delta T cells, LAVA aims to deliver potent, targeted antitumor activity while minimizing the off-target effects often seen with conventional T-cell engagers.

The company’s lead programs include LAVA-051, currently in early-phase clinical trials for relapsed or refractory B-cell malignancies, and LAVA-1207, an investigational candidate targeting prostate-specific membrane antigen (PSMA) in prostate cancer. Both candidates are based on the same core platform but are engineered to address hematologic and solid tumor indications, respectively. In preclinical studies, LAVA’s molecules have demonstrated robust tumor cell killing, favorable tissue distribution, and a safety profile that supports their continued clinical evaluation.

Founded in 2018 as a spin-out from leading academic institutions in Belgium, LAVA Therapeutics has rapidly built a multidisciplinary team combining expertise in antibody engineering, tumor immunology, and clinical development. The company is headquartered in Ghent, Belgium, with research and development operations in both Europe and the United States. Its leadership team includes veterans from established biopharmaceutical and oncology companies, guiding LAVA’s advancement through early clinical milestones.

As LAVA progresses its pipeline through clinical stages, the company continues to explore collaborations and partnerships to expand the reach of its gamma-delta T cell engager platform. By focusing on differentiated mechanisms of action and modular design, LAVA Therapeutics aims to address unmet needs across a broad range of oncology indications and establish a new class of targeted immunotherapies.

Key Stats

• Today's Range: $1.56 to $1.63
• 50-Day Range: $1.42 to $1.62
• 52-Week Range: $0.85 to $2.09
• Volume: 71,013 shs
• Average Volume: 439,211 shs
• Market Capitalization: $41.57 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $2.69
• Consensus Rating: Reduce

LAVA Therapeutics Stock Analysis - MarketRank™

LAVA Therapeutics scored higher than 30% of companies evaluated by MarketBeat, and ranked 775th out of 942 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Reduce

Consensus Rating

LAVA Therapeutics has received a consensus rating of Reduce. The company's average rating score is 1.86, and is based on no buy ratings, 6 hold ratings, and 1 sell rating.

Upside Potential

LAVA Therapeutics has a consensus price target of $2.69, representing about 69.9% upside from its current price of $1.58.

Amount of Analyst Coverage

LAVA Therapeutics has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for LAVA Therapeutics are expected to decrease in the coming year, from ($1.13) to ($1.30) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of LAVA Therapeutics is -1.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of LAVA Therapeutics is -1.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

LAVA Therapeutics has a P/B Ratio of 1.49. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.67% of the float of LAVA Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

LAVA Therapeutics has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in LAVA Therapeutics has recently increased by 11.02%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

LAVA Therapeutics does not currently pay a dividend.

Dividend Growth

LAVA Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.67% of the float of LAVA Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

LAVA Therapeutics has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in LAVA Therapeutics has recently increased by 11.02%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

MarketBeat Follows

2 people have added LAVA Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, LAVA Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $6,564,826.00 in company stock.

Percentage Held by Insiders

Only 9.50% of the stock of LAVA Therapeutics is held by insiders.

LVTX Stock Analysis - Frequently Asked Questions

How have LVTX shares performed this year?

LAVA Therapeutics' stock was trading at $0.9510 at the beginning of 2025. Since then, LVTX stock has increased by 66.1% and is now trading at $1.58.

How were LAVA Therapeutics' earnings last quarter?

LAVA Therapeutics N.V. (NASDAQ:LVTX) posted its earnings results on Wednesday, August, 13th. The company reported ($0.32) earnings per share for the quarter, missing the consensus estimate of ($0.28) by $0.04.

When did LAVA Therapeutics IPO?

LAVA Therapeutics (LVTX) raised $100 million in an IPO on Thursday, March 25th 2021. The company issued 6,700,000 shares at $14.00-$16.00 per share. J.P. Morgan, Jefferies and SVB Leerink served as the underwriters for the IPO and Kempen & Co. was co-manager.

How do I buy shares of LAVA Therapeutics?

Shares of LVTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of LAVA Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that LAVA Therapeutics investors own include Broadcom (AVGO), NVIDIA (NVDA), Adobe (ADBE), Arista Networks (ANET), New Oriental Education & Technology Group (EDU), ServiceNow (NOW) and AppLovin (APP).

Company Calendar

• Last Earnings: 8/13/2025
• Today: 10/09/2025
• Next Earnings (Estimated): 12/09/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:LVTX
• CIK: 1840748
• Web: www.lavatherapeutics.com
• Phone: 31-85-016-3100
• Fax: N/A
• Employees: 60
• Year Founded: 2016

Price Target and Rating

• Average Price Target for LAVA Therapeutics: $2.69
• High Price Target: $6.00
• Low Price Target: $1.24
• Potential Upside/Downside: +69.9%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.86
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.05)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$25.11 million
• Net Margins: N/A
• Pretax Margin: -552.14%
• Return on Equity: -106.29%
• Return on Assets: -38.24%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 10.78
• Quick Ratio: 10.78

Sales & Book Value

• Annual Sales: $11.98 million
• Price / Sales: 3.47
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.06 per share
• Price / Book: 1.49

Miscellaneous

• Outstanding Shares: 26,310,000
• Free Float: 23,806,000
• Market Cap: $41.57 million
• Optionable: Optionable
• Beta: 0.50